Indoco Remedies Ltd (INDOCO) Q3FY26 Concall Summary - Dec-2025 Qtr
Performance Overview
- The company reported a better performance in Q3, driven primarily by its exports divisions and API business, which grew by 26.2% and 24% YoY, respectively.
- Subsidiaries such as FPP in the U.S. and Warren Remedies (OTC business) also demonstrated improved performance, with Warren Remedies growing over 43% in the quarter.
- The domestic formulations business remained flat YoY, primarily due to challenges in the acute therapies segment, which was affected by unpredictable primary sales. However, secondary sales and prescription responses remain strong.
- Indoco improved its market position, jumping one rank to 21st in the prescription audit (IQVIA MAT basis) with 10.86 crores prescriptions, surpassing Pfizer.
- The company successfully launched two new OTC products, Sensodent DSP and Sensodent DPC, extending its brand presence in the sensitivity and clean toothpaste segments. New product introductions now contribute 6.5% to India's revenues.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.